Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Casimersen (SRP-4045) for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45

    NEXT STORY
    NuGenerex Immuno-Oncology Announces Shareholder Conference Call July 10, 2020 at 4:15 PM
    PREV STORY
    Ascendis Pharma A/S Announces Submission of Biologics License Application (BLA) to FDA for TransCon™ hGH in Pediatric Growth Hormone Deficiency
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Salarius Pharmaceuticals Reports First Quarter 2020 Financial Results

    author_avatar
    NASDAQ Market News

    Madrigal Pharmaceuticals to Present Secondary Analyses of Data from Phase 2 NASH Study of Resmetirom and Symposium at the Digital International Liver Congress™ 2020

    author_avatar
    NASDAQ Market News

    New Studies Demonstrate the Predictive Value of the Vectra® Test in People Diagnosed with Rheumatoid Arthritis

    author_avatar
    NASDAQ Market News